A New Frontier in the Co-Management of Thyroid Eye Disease
Annenberg Center for Health Sciences
6 episodes
11 hours ago
Thyroid eye disease, also known as Graves’ orbitopathy, is a potentially serious, progressive autoimmune disease that most often occurs in people with hyperthyroidism, ie, Graves’ disease. Kimberley Cockerham, MD, FACS, moderates this series of six, paired conversations between endocrinologist Terry J. Smith, MD, and eye specialists Wendy W. Lee, MD, and Raymond Douglas, MD, PhD, to explore current and emerging treatment options for thyroid eye disease. In these conversations, faculty review the current understanding of the burden and pathophysiology of thyroid eye disease—including treatment
All content for A New Frontier in the Co-Management of Thyroid Eye Disease is the property of Annenberg Center for Health Sciences and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Thyroid eye disease, also known as Graves’ orbitopathy, is a potentially serious, progressive autoimmune disease that most often occurs in people with hyperthyroidism, ie, Graves’ disease. Kimberley Cockerham, MD, FACS, moderates this series of six, paired conversations between endocrinologist Terry J. Smith, MD, and eye specialists Wendy W. Lee, MD, and Raymond Douglas, MD, PhD, to explore current and emerging treatment options for thyroid eye disease. In these conversations, faculty review the current understanding of the burden and pathophysiology of thyroid eye disease—including treatment
A New Frontier in the Co-Management of Thyroid Eye Disease
11 minutes 59 seconds
4 years ago
Patient Evaluation
How patients present with thyroid eye disease
Differential diagnosis for thyroid eye disease
How endocrinologists and ophthalmologists approach patient evaluation
A New Frontier in the Co-Management of Thyroid Eye Disease
Thyroid eye disease, also known as Graves’ orbitopathy, is a potentially serious, progressive autoimmune disease that most often occurs in people with hyperthyroidism, ie, Graves’ disease. Kimberley Cockerham, MD, FACS, moderates this series of six, paired conversations between endocrinologist Terry J. Smith, MD, and eye specialists Wendy W. Lee, MD, and Raymond Douglas, MD, PhD, to explore current and emerging treatment options for thyroid eye disease. In these conversations, faculty review the current understanding of the burden and pathophysiology of thyroid eye disease—including treatment
